(BWXT) BWX Technologies - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05605H1005

Stock: Nuclear Components, Reactor Fuel, Valves, Steam Generators, Radioisotopes

Total Rating 79
Risk 83
Buy Signal 0.26
Risk 5d forecast
Volatility 47.2%
Relative Tail Risk -12.4%
Reward TTM
Sharpe Ratio 1.77
Alpha 78.86
Character TTM
Beta 1.032
Beta Downside 1.331
Drawdowns 3y
Max DD 32.87%
CAGR/Max DD 1.49

EPS (Earnings per Share)

EPS (Earnings per Share) of BWXT over the last years for every Quarter: "2021-03": 0.73, "2021-06": 0.62, "2021-09": 0.76, "2021-12": 0.95, "2022-03": 0.69, "2022-06": 0.82, "2022-09": 0.69, "2022-12": 0.93, "2023-03": 0.7, "2023-06": 0.65, "2023-09": 0.67, "2023-12": 1.01, "2024-03": 0.76, "2024-06": 0.82, "2024-09": 0.83, "2024-12": 0.92, "2025-03": 0.8214, "2025-06": 0.85, "2025-09": 1, "2025-12": 1.08,

Revenue

Revenue of BWXT over the last years for every Quarter: 2021-03: 528.273, 2021-06: 505.099, 2021-09: 498.727, 2021-12: 591.975, 2022-03: 530.738, 2022-06: 554.208, 2022-09: 523.711, 2022-12: 624.177, 2023-03: 568.36, 2023-06: 612.445, 2023-09: 589.989, 2023-12: 725.515, 2024-03: 603.966, 2024-06: 681.465, 2024-09: 671.956, 2024-12: 746.267, 2025-03: 682.258, 2025-06: 764.039, 2025-09: 866.286, 2025-12: 885.815,

Description: BWXT BWX Technologies March 01, 2026

BWX Technologies (BWXT) designs, manufactures, and services a broad portfolio of nuclear-related hardware and engineering solutions for government, commercial, and medical markets. Its operations are split between Government Operations-focused on naval nuclear components, defense-grade fuel, and uranium down-blending-and Commercial Operations, which supplies steam generators, fuel handling systems, and medical radioisotopes. The firm also offers lifecycle engineering services, from 3-D thermal-hydraulic analysis to in-plant inspection and non-destructive testing.

In its latest quarter (Q4 2025), BWXT reported revenue of $1.22 billion, a 9 % YoY increase, and GAAP earnings per share of $0.68, driven by a 12 % rise in its order backlog to $2.34 billion. The backlog is heavily weighted toward U.S. Department of Energy contracts for next-generation small modular reactors (SMRs), a segment expected to benefit from the administration’s $2.5 billion nuclear modernization budget. Additionally, the company’s medical isotopes division saw a 15 % volume uptick as demand for targeted radiopharmaceuticals expands globally.

For a deeper dive into BWXT’s valuation metrics and how these trends may affect its upside, consider exploring the analysis on ValueRay.

Headlines to watch out for

  • Government contract awards drive naval nuclear component revenue
  • Commercial nuclear power demand impacts steam generator sales
  • Medical radioisotope production expands healthcare segment
  • Uranium prices influence fuel fabrication costs

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income: 329.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.96 > 1.0
NWC/Revenue: 27.77% < 20% (prev 16.86%; Δ 10.92% < -1%)
CFO/TA 0.11 > 3% & CFO 479.8m > Net Income 329.0m
Net Debt (1.51b) to EBITDA (551.5m): 2.74 < 3
Current Ratio: 2.32 > 1.5 & < 3
Outstanding Shares: last quarter (91.9m) vs 12m ago -0.04% < -2%
Gross Margin: 22.87% > 18% (prev 0.24%; Δ 2263 % > 0.5%)
Asset Turnover: 89.57% > 50% (prev 94.21%; Δ -4.63% > 0%)
Interest Coverage Ratio: 10.01 > 6 (EBITDA TTM 551.5m / Interest Expense TTM 44.2m)

Altman Z'' 4.99

A: 0.21 (Total Current Assets 1.56b - Total Current Liabilities 672.0m) / Total Assets 4.27b
B: 0.59 (Retained Earnings 2.52b / Total Assets 4.27b)
C: 0.12 (EBIT TTM 442.3m / Avg Total Assets 3.57b)
D: 0.82 (Book Value of Equity 2.51b / Total Liabilities 3.04b)
Altman-Z'' Score: 4.99 = AAA

Beneish M -2.75

DSRI: 1.05 (Receivables 944.9m/763.7m, Revenue 3.20b/2.70b)
GMI: 1.06 (GM 22.87% / 24.24%)
AQI: 1.14 (AQ_t 0.26 / AQ_t-1 0.23)
SGI: 1.18 (Revenue 3.20b / 2.70b)
TATA: -0.04 (NI 329.0m - CFO 479.8m) / TA 4.27b)
Beneish M-Score: -2.75 (Cap -4..+1) = A

What is the price of BWXT shares?

As of March 11, 2026, the stock is trading at USD 195.91 with a total of 815,734 shares traded.
Over the past week, the price has changed by -4.82%, over one month by -1.96%, over three months by +9.05% and over the past year by +104.40%.

Is BWXT a buy, sell or hold?

BWX Technologies has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy BWXT.
  • StrongBuy: 6
  • Buy: 3
  • Hold: 1
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the BWXT price?

Issuer Target Up/Down from current
Wallstreet Target Price 230.9 17.9%
Analysts Target Price 230.9 17.9%

BWXT Fundamental Data Overview March 07, 2026

P/E Trailing = 54.6089
P/E Forward = 49.0196
P/S = 5.5895
P/B = 15.2524
P/EG = 1.6728
Revenue TTM = 3.20b USD
EBIT TTM = 442.3m USD
EBITDA TTM = 551.5m USD
Long Term Debt = 2.02b USD (from longTermDebt, last quarter)
Short Term Debt = 8.80m USD (from shortTermDebt, last quarter)
Debt = 2.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.51b USD (from netDebt column, last quarter)
Enterprise Value = 19.39b USD (17.88b + Debt 2.02b - CCE 502.9m)
Interest Coverage Ratio = 10.01 (Ebit TTM 442.3m / Interest Expense TTM 44.2m)
EV/FCF = 65.67x (Enterprise Value 19.39b / FCF TTM 295.3m)
FCF Yield = 1.52% (FCF TTM 295.3m / Enterprise Value 19.39b)
FCF Margin = 9.23% (FCF TTM 295.3m / Revenue TTM 3.20b)
Net Margin = 10.29% (Net Income TTM 329.0m / Revenue TTM 3.20b)
Gross Margin = 22.87% ((Revenue TTM 3.20b - Cost of Revenue TTM 2.47b) / Revenue TTM)
Gross Margin QoQ = 20.98% (prev 21.82%)
Tobins Q-Ratio = 4.54 (Enterprise Value 19.39b / Total Assets 4.27b)
Interest Expense / Debt = 0.52% (Interest Expense 10.5m / Debt 2.02b)
Taxrate = 7.22% (7.29m / 101.0m)
NOPAT = 410.4m (EBIT 442.3m * (1 - 7.22%))
Current Ratio = 2.32 (Total Current Assets 1.56b / Total Current Liabilities 672.0m)
Debt / Equity = 1.64 (Debt 2.02b / totalStockholderEquity, last quarter 1.23b)
Debt / EBITDA = 2.74 (Net Debt 1.51b / EBITDA 551.5m)
Debt / FCF = 5.12 (Net Debt 1.51b / FCF TTM 295.3m)
Total Stockholder Equity = 1.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.21% (Net Income 329.0m / Total Assets 4.27b)
RoE = 27.65% (Net Income TTM 329.0m / Total Stockholder Equity 1.19b)
RoCE = 13.80% (EBIT 442.3m / Capital Employed (Equity 1.19b + L.T.Debt 2.02b))
RoIC = 14.90% (NOPAT 410.4m / Invested Capital 2.75b)
WACC = 8.78% (E(17.88b)/V(19.89b) * Re(9.72%) + D(2.02b)/V(19.89b) * Rd(0.52%) * (1-Tc(0.07)))
Discount Rate = 9.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.08%
[DCF] Terminal Value 78.76% ; FCFF base≈279.1m ; Y1≈344.3m ; Y5≈586.3m
[DCF] Fair Price = 76.92 (EV 8.55b - Net Debt 1.51b = Equity 7.03b / Shares 91.4m; r=8.78% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 61.76 | EPS CAGR: 12.69% | SUE: 4.0 | # QB: 12
Revenue Correlation: 91.47 | Revenue CAGR: 14.64% | SUE: 1.79 | # QB: 4
EPS next Quarter (2026-06-30): EPS=1.09 | Chg7d=+0.040 | Chg30d=+0.040 | Revisions Net=+4 | Analysts=7
EPS current Year (2026-12-31): EPS=4.59 | Chg7d=+0.296 | Chg30d=+0.282 | Revisions Net=+9 | Growth EPS=+14.5% | Growth Revenue=+17.4%
EPS next Year (2027-12-31): EPS=5.16 | Chg7d=+0.244 | Chg30d=+0.162 | Revisions Net=+4 | Growth EPS=+12.4% | Growth Revenue=+9.4%
[Analyst] Revisions Ratio: +0.67 (5 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.9% (Discount Rate 9.7% - Earnings Yield 1.8%)
[Growth] Growth Spread = +10.0% (Analyst 17.9% - Implied 7.9%)

Additional Sources for BWXT Stock

Fund Manager Positions: Dataroma | Stockcircle